2. Федеральная служба государственной статистики. Доступ: https://rosstat.gov.ru/sdg/data/goal3 (дата обращения – 01.08.2023). [Federal State Statistics Service (Russia). URL: https://rosstat.gov.ru/sdg/data/goal3 (date of access – 01.08.2023) (In Russ.)].

3. Weissman S., Sinh P., Mehta T.I. et. al. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. World J Gastrointest Pathophysiol. 2020; 11(5): 104–13. https://dx.doi.org/10.4291/wjgp.v11.i5.104.

4. Pepe M., Carulli E., Forleo C. et. al. Inflammatory bowel disease and acute coronary syndromes: From pathogenesis to the fine line between bleeding and ischemic risk. Inflamm Bowel Dis. 2021; 27(5): 725–31. https://dx.doi.org/10.1093/ibd/izaa160.

5. Le Gall G., Kirchgesner J., Bejaoui M. et. al. Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. 2018; 13(8): e0201991. https://dx.doi.org/10.1371/journal.pone.0201991.

6. Pemmasani G., Elgendy I., Mamas M.A. et al. Epidemiology and clinical outcomes of patients with inflammatory bowel disease presenting with acute coronary syndrome. Inflamm Bowel Dis. 2021; 27(7): 1017–25. https://dx.doi.org/10.1093/ibd/izaa237.

7. Nguyen N.H., Ohno-Machado L., Sandborn W.J., Singh S. Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2018; 24(4): 916–23. https://dx.doi.org/10.1093/ibd/izx089.

8. Pepe M., Cecere A., D’Alessandro P. et. al. Massive stent thrombosis during active ulcerative colitis: The tricky balance between manifest hemorrhagic and concealed thrombotic risk. Clin Exp Med. 2018; 18(4): 481–85. https://dx.doi.org/10.1007/s10238-018-0522-5.

9. Yarur A.J., Deshpande A.R., Pechman D.M. et. al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011; 106(4): 741–47. https://dx.doi.org/10.1038/ajg.2011.63.

10. Gravina A.G., Dallio M., Masarone M. et. al. Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets. Oxid Med Cell Longev. 2018; 2018: 1–12. https://dx.doi.org/10.1155/2018/2568569.

11. Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011; 6 Suppl 1: 45–51. https://dx.doi.org/10.1007/s11739-011-0669-5.

12. Ridker P.M. Will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020; 141(10): 787–89. https://dx.doi.org/10.1161/CIRCULATIONAHA.119.045256.

13. Ridker P.M. Residual inflammatory risk: Addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016; 37(22): 1720–22. https://dx.doi.org/10.1093/eurheartj/ehw024.

14. Магрук М.А., Мосикян А.А., Бабенко А.Ю. Биомаркеры, ассоциированные с атерогенезом: актуальный статус и перспективные направления. Российский кардиологический журнал. 2019; 24(12): 148–152 [Magruk M.A., Mosikyan A.A., Babenko A.Yu. Biomarkers associated with atherogenesis: Current status and promising areas. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2019; 24(12): 148–152 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2019-12-148-152. EDN: PBYHYJ.

15. Ridker P.M., Rifai N., Rose L. et. al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347(20): 1557–65. https://dx.doi.org/10.1056/NEJMoa021993.

16. Agouridis A.P., Elisaf M., Milionis H.J. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol. 2011; 24(3): 181–87.

17. Zanoli L., Inserra G., Castellino P. Increased cardiovascular risk in subjects with a low prevalence of classic cardiovascular risk factors: The inflammatory bowel disease paradox. Trends Cardiovasc Med. 2015; 25(8): 705–6. https://dx.doi.org/10.1016/j.tcm.2015.04.001.

18. Filimon A.M., Negreanu L., Doca M. et. al. Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons. World J Gastroenterol. 2015; 21(33): 9688–92. https://dx.doi.org/10.3748/wjg.v21.i33.9688.

19. Fumery M., Xiaocang C., Dauchet L. et. al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014; 8(6): 469–79. https://dx.doi.org/10.1016/j.crohns.2013.09.021.

20. Миронова О.Ю., Исайкина М.А., Хасиева С.А. Атеросклероз и сердечно-сосудистый риск у пациентов с воспалительными заболеваниями кишечника. Терапевтический архив. 2021; 93(12): 1533–1538. [Mironova O.I., Isaikina M.A., Khasieva S.A. Аtherosclerosis and cardiovascular risk in patients with inflammatory bowel disease. Terapevticheskiy arkhiv = Therapeutic Archive. 2021; 93(12): 1533–1538 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2021.12.201225. EDN: HJJJXN.

21. Лищинская А.А., Князев О.В., Каграманова А.В. с соавт. Частота и факторы риска тромбоэмболических осложнений у пациентов с воспалительными заболеваниями кишечника. Терапевтический архив. 2022; 94(2): 172–179. [Lishchinskaya A.A., Knyazev O.V., Kagramanova A.V. et. al. Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases. Terapevticheskiy arkhiv = Therapeutic Archive. 2022; 94(2): 172–179 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2022.02.201367. EDN: CSRIWV.

22. Andersen N.N., Jess T. Risk of cardiovascular disease in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2014; 5(3): 359–65. https://dx.doi.org/10.4291/wjgp.v5.i3.359.

23. Wu P., Jia F., Zhang B. et. al. Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med. 2017; 13(2): 395–400. https://dx.doi.org/10.3892/etm.2016.3966.

24. Бабаева Г.Г., Бабаев З.М. Частота выявления некоторых маркеров эндотелиальной дисфункции у больных с воспалительными заболеваниями кишечника. Терапевтический архив. 2018; 90(4): 12–16. [Babayeva G.H., Babayeva Z.M. Frequency of detection of some markers of endothelial dysfunction in patients with inflammatory bowel diseases. Terapevticheskiy arkhiv = Therapeutic Archive. 2018; 90(4): 12–16 (In Russ.)]. https://dx.doi.org/10.26442/terarkh201890412-16. EDN: YVQZQA.

25. Гриневич В. Б., Радченко В. Г. Микробиота кишечника и метаболический синдром. Экспериментальная и клиническая гастроэнтерология. 2020; 183(11): 11–19. [Grinevich V.B., Radchenko V. G. Gut microbiota and metabolic syndrome. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2020; 183(11): 11–19 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-183-11-11-19. EDN: GZNZHU.

26. Kristensen S.L., Ahlehoff O., Lindhardsen J. et. al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS One. 2013; 8(2): e56944. https://dx.doi.org/10.1371/journal.pone.0056944.

27. Feng W., Chen G., Cai D. et al. Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies. J Am Heart Assoc. 2017; 6(8): e005892. https://dx.doi.org/10.1161/JAHA.117.005892.